サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：上気道疾患治療の世界市場：2023～2030年
市場調査レポート
商品コード
1351035

上気道疾患治療の世界市場：2023～2030年

Global Upper Respiratory Tract Disease Treatment Market 2023-2030
出版日: | 発行: Orion Market Research | ページ情報: 英文 140 Pages | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
上気道疾患治療の世界市場：2023～2030年
出版日: 2023年09月14日
発行: Orion Market Research
ページ情報: 英文 140 Pages
納期: 2～3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の上気道疾患治療市場は、予測期間中（2023～2030年）にCAGR 3.6％で成長すると予測されています。上気道感染症（URTI）とは、鼻、副鼻腔、咽頭、喉頭などの上気道を侵す急性感染症の結果生じる病気です。一般的には、鼻閉、咽頭痛、扁桃炎、咽頭炎、喉頭炎、中耳炎、風邪などがこれにあたります。この感染症は、細菌やウイルスのような病気の原因となる病原体を標的に、さまざまな薬剤を用いて治療することができます。喘息、うっ血性心不全、COPDを患う成人の増加は、呼吸器合胞体ウイルス感染症にかかるリスクが高く、市場の成長につながります。米国plos computing biologyの研究によると、呼吸器症候群は様々な細菌やウイルスによって引き起こされ、感染症は軽い風邪から生命を脅かす肺炎まで様々です。最も一般的な疾患の1つであるURTIの2019年の世界の負担は172億と推定されています。URTIに罹患する個人の大半は軽度の症状を呈するが、米国だけでもインフルエンザに関連しないウイルス性URTIの経済的負担は225億米ドルと推定され、URTIの市販治療に20億米ドルが費やされていると推定されます。

セグメント別の展望

感染性または細菌性疾患。また、上気道感染症による医師の往診が増加し、これらの感染症を治療するための市販薬の需要が高まっています。

上気道感染症治療の世界市場では、抗生物質のサブセグメントが大きなシェアを占めると予想されます。

薬剤クラス別では、抗生物質サブセグメントが世界の上気道疾患市場でかなりのシェアを占めると予想されます。このセグメントの成長は、アフリカ、スリランカ、パキスタンのような多くの国々で、上気道疾患の症例が増加していること、医師や適切な医療処方が利用可能で安価に入手できないことに起因しています。上気道感染症やその症状を治療するための抗生物質が容易に入手できることから、抗生物質に対する需要が増加し、上気道感染症治療市場を牽引することになります。

地域展望

世界の上気道感染症治療市場は、北米（米国、カナダ）、欧州（英国、イタリア、スペイン、ドイツ、フランス、その他欧州地域）、アジア太平洋地域（インド、中国、日本、韓国、その他アジア地域）、その他世界地域（中東とアフリカ、ラテンアメリカ）を含む地域別にさらに細分化されています。このうち、アジア太平洋地域は、中国、インド、インドネシアなどの国々における細菌性疾患やウイルス性疾患の増加による需要増のため、世界市場で突出したシェアを占めると予想されます。

北米地域は世界の上気道疾患治療市場において顕著なCAGRで成長する見込み

すべての地域の中で、北米地域は予測期間中にかなりのCAGRで成長すると予想されています。この地域の成長は、急激な気候の変化とタバコの消費量の増加により、上気道感染症の有病率が増加していることに起因しています。咳止め薬、鼻腔充血除去薬、鼻洗浄薬の需要増加によるものです。米国国立医学図書館の報告によると、2022年9月、タバコの喫煙に関連する慢性疾患には、呼吸器疾患、心血管疾患、がん、糖尿病が含まれます。推定1600万人の米国成人が喫煙に関連した病気と共存しています。喫煙は慢性疾患とそれに続く合併症のリスクを高め、生活の質を全体的に低下させる。

したがって、上気道疾患治療市場ソリューションの採用に向けて国のかなりのシフトがあります。治療に関する意識の高まりと、特に新興国における可処分所得の増加は、業界の成長を促進すると期待されています。

目次

第1章 レポート概要

  • 業界の現状分析と成長ポテンシャルの展望
  • 調査方法とツール
  • 市場内訳
    • セグメント別
    • 地域別

第2章 市場概要と洞察

  • 調査範囲
  • アナリストの洞察と現在の市場動向
    • 主な調査結果
    • 推奨事項
    • 結論

第3章 競合情勢

  • 主要企業分析
  • F. Hoffmann-La Roche Ltd
    • 概要
    • 財務分析
    • SWOT分析
    • 最近の動向
  • Pfizer Inc.
    • 会社概要
    • 財務分析
    • SWOT分析
    • 最近の動向
  • Teva Pharmaceutical Industries Ltd.
    • 概要
    • 財務分析
    • SWOT分析
    • 最近の動向
  • 主要戦略分析

第4章 市場セグメンテーション

  • 上気道疾患治療の世界市場：カテゴリー別
    • 一般用医薬品
    • 処方薬
  • 上気道疾患治療の世界市場：治療別
    • 局所治療
    • 咳止め薬
    • 鼻腔充血除去薬
    • その他（抗ヒスタミン薬、グアイフェネシン、クロモリン）
  • 上気道疾患治療の世界市場：薬剤クラス別
    • 非ステロイド性抗炎症薬
    • 抗生物質
    • その他（イブプロフェン）

第5章 地域別分析

  • 北米
    • 米国
    • カナダ
  • 欧州
    • 英国
    • ドイツ
    • イタリア
    • スペイン
    • フランス
    • その他欧州
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • 韓国
    • その他アジア太平洋地域
  • 世界のその他の地域

第6章 企業プロファイル

  • Alcon, Inc.
  • AstraZeneca Plc
  • Cipla Limited
  • CSL Ltd.
  • Dr. Reddy's Laboratories Ltd.
  • F. Hoffmann-La Roche Ltd
  • GlaxoSmithKline plc
  • Lupin Limited
  • ベンダーの市場ポジショニング
  • Merck & Co., Inc.
  • Novartis AG
  • Regeneron Pharmaceuticals Inc.
  • Sandoz, Inc.
  • Sanofi
  • Teva Pharmaceutical Industries Ltd.
図表

LIST OF TABLES

  • 1. GLOBAL UPPER RESPIRATORY TRACT DISEASE TREATMENT MARKET RESEARCH AND ANALYSIS BY CATEGORY, 2022-2030 ($ MILLION)
  • 2. GLOBAL OTC FOR UPPER RESPIRATORY TRACT DISEASE TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION,2022-2030 ($ MILLION)
  • 3. GLOBAL PRESCRIPTION UPPER RESPIRATORY TRACT DISEASE TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 4. GLOBAL UPPER RESPIRATORY TRACT DISEASE TREATMENT MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2022-2030 ($ MILLION)
  • 5. GLOBAL TOPICAL TREATMENT FOR UPPER RESPIRATORY TRACT DISEASE MARKET RESEARCH AND ANALYSIS, 2022-2030 ($ MILLION)
  • 6. GLOBAL COUGH SUPPRESSANT UPPER RESPIRATORY TRACT DISEASE TREATMENT MARKET RESEARCH AND ANALYSIS, 2022-2030 ($ MILLION)
  • 7. GLOBAL NASAL DECONGESTANT UPPER RESPIRATORY TRACT DISEASE TREATMENT MARKET RESEARCH AND ANALYSIS, 2022-2030 ($ MILLION)
  • 8. GLOBAL OTHER TREATMENT FOR UPPER RESPIRATORY TRACT DISEASE MARKET RESEARCH AND ANALYSIS, 2022-2030 ($ MILLION)
  • 9. GLOBAL UPPER RESPIRATORY TRACT DISEASE TREATMENT MARKET RESEARCH AND ANALYSIS BY DRUG CLASS, 2022-2030 ($ MILLION)
  • 10. GLOBAL NSAID FOR UPPER RESPIRATORY TRACT DISEASE TREATMENT MARKET RESEARCH AND ANALYSIS, 2022-2030 ($ MILLION)
  • 11. GLOBAL ANTIBIOTICS FOR UPPER RESPIRATORY TRACT DISEASE TREATMENT FOR AUTOMOTIVE MARKET RESEARCH AND ANALYSIS, 2022-2030 ($ MILLION)
  • 12. GLOBAL OTHER DRUGS FOR UPPER RESPIRATORY TRACT DISEASE TREATMENT FOR HEALTHCARE MARKET RESEARCH AND ANALYSIS, 2022-2030 ($ MILLION)
  • 13. GLOBAL UPPER RESPIRATORY TRACT DISEASE TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 14. NORTH AMERICAN UPPER RESPIRATORY TRACT DISEASE TREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 15. NORTH AMERICAN UPPER RESPIRATORY TRACT DISEASE TREATMENT MARKET RESEARCH AND ANALYSIS BY CATEGORY, 2022-2030 ($ MILLION)
  • 16. NORTH AMERICAN UPPER RESPIRATORY TRACT DISEASE TREATMENT MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2022-2030 ($ MILLION)
  • 17. NORTH AMERICAN UPPER RESPIRATORY TRACT DISEASE TREATMENT MARKET RESEARCH AND ANALYSIS BY DRUG CLASS, 2022-2030 ($ MILLION)
  • 18. EUROPEAN UPPER RESPIRATORY TRACT DISEASE TREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 19. EUROPEAN UPPER RESPIRATORY TRACT DISEASE TREATMENT MARKET RESEARCH AND ANALYSIS BY CATEGORY, 2022-2030 ($ MILLION)
  • 20. EUROPEAN UPPER RESPIRATORY TRACT DISEASE TREATMENT MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2022-2030 ($ MILLION)
  • 21. EUROPEAN UPPER RESPIRATORY TRACT DISEASE TREATMENT MARKET RESEARCH AND ANALYSIS BY DRUG CLASS, 2022-2030 ($ MILLION)
  • 22. ASIA- PACIFIC UPPER RESPIRATORY TRACT DISEASE TREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 23. ASIA- PACIFIC UPPER RESPIRATORY TRACT DISEASE TREATMENT MARKET RESEARCH AND ANALYSIS BY CATEGORY, 2022-2030 ($ MILLION)
  • 24. ASIA- PACIFIC UPPER RESPIRATORY TRACT DISEASE TREATMENT MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2022-2030 ($ MILLION)
  • 25. ASIA- PACIFIC UPPER RESPIRATORY TRACT DISEASE TREATMENT MARKET RESEARCH AND ANALYSIS BY DRUG CLASS, 2022-2030 ($ MILLION)
  • 26. REST OF THE WORLD UPPER RESPIRATORY TRACT DISEASE TREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 27. REST OF THE WORLD UPPER RESPIRATORY TRACT DISEASE TREATMENT MARKET RESEARCH AND ANALYSIS BY CATEGORY, 2022-2030 ($ MILLION)
  • 28. REST OF THE WORLD UPPER RESPIRATORY TRACT DISEASE TREATMENT MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2022-2030 ($ MILLION)
  • 29. REST OF THE WORLD UPPER RESPIRATORY TRACT DISEASE TREATMENT MARKET RESEARCH AND ANALYSIS BY DRUG CLASS, 2022-2030 ($ MILLION)

LIST OF FIGURES

  • 1. GLOBAL UPPER RESPIRATORY TRACT DISEASE TREATMENT MARKET SHARE BY CATEGORY, 2022 VS 2030 (%)
  • 2. GLOBAL OTC FOR UPPER RESPIRATORY TRACT DISEASE TREATMENT MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 3. GLOBAL PRESCRIPTION FOR UPPER RESPIRATORY TRACT DISEASE TREATMENT MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 4. GLOBAL UPPER RESPIRATORY TRACT DISEASE TREATMENT MARKET SHARE BY TREATMENT, 2022 VS 2030 (%)
  • 5. GLOBAL TOPICAL TREATMENT FOR UPPER RESPIRATORY TRACT DISEASE TREATMENT MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 6. GLOBAL COUGH SUPPRESSANT UPPER RESPIRATORY TRACT DISEASE TREATMENT MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 7. GLOBAL NASAL DECONGESTANT UPPER RESPIRATORY TRACT DISEASE TREATMENT MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 8. GLOBAL OTHER TREATMENTS FOR UPPER RESPIRATORY TRACT DISEASE MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 9. GLOBAL UPPER RESPIRATORY TRACT DISEASE TREATMENT MARKET SHARE ANALYSIS BY DRUG CLASS, 2022-2030 ($ MILLION)
  • 10. GLOBAL NSAID FOR UPPER RESPIRATORY TRACT DISEASE TREATMENT ON BFSI MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 11. GLOBAL ANTIBIOTICS FOR UPPER RESPIRATORY TRACT DISEASE TREATMENT MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 12. GLOBAL OTHER DRUGS FOR UPPER RESPIRATORY TRACT DISEASE TREATMENT MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 13. GLOBAL UPPER RESPIRATORY TRACT DISEASE TREATMENT MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 14. US UPPER RESPIRATORY TRACT DISEASE TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 15. CANADA UPPER RESPIRATORY TRACT DISEASE TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 16. UK UPPER RESPIRATORY TRACT DISEASE TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 17. FRANCE UPPER RESPIRATORY TRACT DISEASE TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 18. GERMANY UPPER RESPIRATORY TRACT DISEASE TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 19. ITALY UPPER RESPIRATORY TRACT DISEASE TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 20. SPAIN UPPER RESPIRATORY TRACT DISEASE TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 21. REST OF EUROPE UPPER RESPIRATORY TRACT DISEASE TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 22. INDIA UPPER RESPIRATORY TRACT DISEASE TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 23. CHINA UPPER RESPIRATORY TRACT DISEASE TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 24. JAPAN UPPER RESPIRATORY TRACT DISEASE TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 25. SOUTH KOREA UPPER RESPIRATORY TRACT DISEASE TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 26. REST OF ASIA-PACIFIC UPPER RESPIRATORY TRACT DISEASE TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 27. REST OF THE WORLD UPPER RESPIRATORY TRACT DISEASE TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
目次
Product Code: OMR2027636

Title: Global Upper Respiratory Tract Disease Treatment Market Size, Share & Trends Analysis Report by Category (OTC and Prescription), by treatment (topical treatment, cough suppressant, nasal decongestant and other), and by drug class (NSAID, antibiotics and others),Forecast Period (2023-2030).

The global upper respiratory tract disease treatment market is anticipated to grow at a CAGR of 3.6% during the forecast period (2023-2030). upper respiratory tract infection (URTI) is an illness, which is the result of an acute infection involving a person's upper respiratory tract like the nose, sinuses, pharynx, or larynx. The infection commonly includes nasal obstruction, sore throat, tonsillitis, pharyngitis, laryngitis, otitis media, and the common cold. This can be treated using various drugs, targeting disease-causing pathogens like bacteria and viruses. Increasing number of Adults with asthma, congestive heart failure, and COPD are at higher risk of suffering from respiratory syncytial virus infection lead to the growth of the market. According to a study of plos computing biology US, URTD caused by a variety of bacteria and viruses, and the infection can vary from a mild cold to life-threatening pneumonia. Being one of the most common diseases, the global burden of URTI in 2019 is estimated to be 17.2 billion. Although a majority of individuals contracting URTIs present mild symptoms, the estimated economic burden of non-influenza related viral URTIs in the United States alone is estimated to be 22.5 billion USD and an estimated $2 billion is spent on over-the-counter treatments for URTIs.

Segmental Outlook

The global upper respiratory tract disease treatment market is segmented on the category, treatment, and drug class. Based on the category, the market is sub-segmented into OTC and Prescription. Based on the treatment, the market is sub-segmented into topical treatment, cough suppressant, nasal decongestant and other. Further, on the basis of drug class, the market is sub-segmented into NSAID, antibiotics and others. Among the category, the OTC sub-segment is anticipated to hold a considerable share of the market owing to its easy availability without any prescription and it is effective in treating

Inflectional or bacterial diseases. Also increase in the home visits by physicians due to upper respiratory tract infections and escalating demand for over the counter medicines to treat these infections.

The Antibiotic Sub-Segment is Anticipated to Hold a Considerable Share of the Global Upper Respiratory Tract Disease Treatment Market

Among the drug class, the antibiotic sub-segment is expected to hold a considerable share of the global upper respiratory tract disease market. The segmental growth is attributed to the growing cases of upper respiratory tract disease and lack of availability and affordability of doctors and proper medical prescription in many countries such as Africa, Sri Lanka, and Pakistan. Which lead to increase in demand for antibiotics owing to its easy availability of antibiotics to treat upper respiratory tract infections and their symptoms will drive the upper respiratory tract infection treatment market.

Regional Outlook

The global Upper Respiratory Tract Disease Treatment market is further segmented based on geography including North America (the US, and Canada), Europe (UK, Italy, Spain, Germany, France, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, and Rest of Asia), and the Rest of the World (the Middle East & Africa, and Latin America). Among these, Asia pacific is anticipated to hold a prominent share of the market across the globe, owing to rise in demand due to increasing case of bacterial and viral diseases in the countries like china, India and Indonesia.

The North America Region is Expected to Grow at a Significant CAGR in the Global Upper Respiratory Tract Disease Treatment Market

Among all regions, the North America regions is anticipated to grow at a considerable CAGR over the forecast period. Regional growth is attributed to increasing prevalence of upper respiratory tract infections in the region due to sudden climate changes and increasing consumption of cigarette. Owing to Increase in demand for Cough suppressants, nasal decongestants, and nasal washes. According to a report of national library of medicine US, in September 2022, chronic diseases associated with cigarette smoking include respiratory and cardiovascular diseases, cancers, and diabetes. An estimated 16 million US adults live with a smoking-related disease. Cigarette smoking can increase the risk of chronic disease and subsequent complications and can lead to overall reduced quality of life.

Hence, there is considerable shift of the country towards the adoption of the Upper Respiratory Tract Disease Treatment market solutions. The growing awareness regarding the treatment and the rising disposable income, especially in emerging economies, are expected to drive the industry growth.

Market Players Outlook

The major companies serving the upper respiratory tract disease treatment market include: AbbVie Inc., GlaxoSmithKline plc, Johnson & Johnson Pvt. Ltd., Merck & Co., Inc., Novartis AG, Takeda Pharmaceutical Company Ltd., and others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers and acquisitions, partnerships, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in April 2022, Pfizer Inc. and ReViral Ltd. announced that the two companies have entered into a binding agreement under which Pfizer will acquire ReViral. ReViral is a clinical-stage biopharmaceutical company with a focus on finding, developing, and commercializing novel antiviral therapeutics that target respiratory syncytial virus (RSV).

The Report Covers:

  • Market value data analysis of 2022 and forecast to 2030.
  • Annualized market revenues ($ million) for each market segment.
  • Country-wise analysis of major geographical regions.
  • Key companies operating in the global upper respiratory tract disease treatment market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
  • Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
  • Analysis of market-entry and market expansion strategies.
  • Competitive strategies by identifying 'who-stands-where' in the market.

Table of Contents

1. Report Summary

  • Current Industry Analysis and Growth Potential Outlook
  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. By Region

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion

3. Competitive Landscape

  • 3.1. Key Company Analysis
  • 3.2. F. Hoffmann-La Roche Ltd
    • 3.2.1. Overview
    • 3.2.2. Financial Analysis
    • 3.2.3. SWOT Analysis
    • 3.2.4. Recent Developments
  • 3.3. Pfizer Inc.
    • 3.3.1. Overview
    • 3.3.2. Financial Analysis
    • 3.3.3. SWOT Analysis
    • 3.3.4. Recent Developments
  • 3.4. Teva Pharmaceutical Industries Ltd.
    • 3.4.1. Overview
    • 3.4.2. Financial Analysis
    • 3.4.3. SWOT Analysis
    • 3.4.4. Recent Developments
  • 3.5. Key Strategy Analysis

4. Market Segmentation

  • 4.1. Global Upper respiratory tract disease Treatment Market by Category
    • 4.1.1. OTC
    • 4.1.2. Prescription
  • 4.2. Global Upper respiratory tract disease Treatment Market by Treatment
    • 4.2.1. Topical treatment
    • 4.2.2. Cough Suppressant
    • 4.2.3. Nasal Decongestant
    • 4.2.4. Others (Antihistamines, Guaifenesin, and Cromolyn)
  • 4.3. Global Upper respiratory tract disease Treatment Market by Drug class
    • 4.3.1. NSAID
    • 4.3.2. Antibiotics
    • 4.3.3. Others (Ibuprofen)

5. Regional Analysis

  • 5.1. North America
    • 5.1.1. United States
    • 5.1.2. Canada
  • 5.2. Europe
    • 5.2.1. UK
    • 5.2.2. Germany
    • 5.2.3. Italy
    • 5.2.4. Spain
    • 5.2.5. France
    • 5.2.6. Rest of Europe
  • 5.3. Asia-Pacific
    • 5.3.1. China
    • 5.3.2. India
    • 5.3.3. Japan
    • 5.3.4. South Korea
    • 5.3.5. Rest of Asia-Pacific
  • 5.4. Rest of the World

6. Company Profiles

  • 6.1. Alcon, Inc.
  • 6.2. AstraZeneca Plc
  • 6.3. Cipla Limited
  • 6.4. CSL Ltd.
  • 6.5. Dr. Reddy's Laboratories Ltd.
  • 6.6. F. Hoffmann-La Roche Ltd
  • 6.7. GlaxoSmithKline plc
  • 6.8. Lupin Limited
  • 6.9. Market positioning of vendors
  • 6.10. Merck & Co., Inc.
  • 6.11. Novartis AG
  • 6.12. Regeneron Pharmaceuticals Inc.
  • 6.13. Sandoz, Inc.
  • 6.14. Sanofi
  • 6.15. Teva Pharmaceutical Industries Ltd.